{
  "as_of": "2026-11-14",
  "slug": "urticaria",
  "title": "蕁麻疹新藥全景",
  "title_en": "Chronic Urticaria Drug Landscape",
  "scope": "慢性自發性蕁麻疹（CSU）與慢性誘發性蕁麻疹（CIndU）分列；不以不同分型或試驗的反應率排行。",
  "scope_en": "CSU and chronic inducible urticaria (CIndU) are separate populations; response rates across subtypes or trials do not establish an efficacy ranking.",
  "short_answers": [
    "諾華在 2026-11-12 公告中確認 Rhapsido 已獲美國核准用於 CSU 與症狀性皮膚劃紋症；本頁以核准進度辨識領先者，不跨試驗比較療效。",
    "諾華於 2026-11-12 公布 RemIND：原始 Rhapsido 組症狀性皮膚劃紋症患者第 52 週完全或部分反應率為 46.8%。",
    "Celldex 於 2026-11-05 預計在 2027 年提交 barzolvolimab 的 CSU 上市申請；申請能否被受理，是下一個會改變核准梯隊的事件。"
  ],
  "short_answers_en": [
    "Novartis confirmed on 2026-11-12 that Rhapsido had US approvals for CSU and symptomatic dermographism; leadership here refers to regulatory progress, without a cross-trial efficacy ranking.",
    "Novartis reported on 2026-11-12 that 46.8% of symptomatic dermographism patients originally assigned Rhapsido had a complete or partial response at Week 52 in RemIND.",
    "Celldex said on 2026-11-05 that it expected to submit a CSU application for barzolvolimab in 2027; filing and acceptance could change the regulatory field."
  ],
  "asia_section": "台灣來源的 UB-221 現以 CUE-221 在大中華區外開發；Genesis 保留中國、香港、澳門及台灣權利。中國二期收納 145 人，omalizumab 為未預設統計比較的對照。韓國 Yuhan 的 lesigercept 另有日本登錄的 CSU 二期試驗。",
  "asia_section_en": "Taiwan-origin UB-221 is being developed as CUE-221 outside Greater China; Genesis retains China, Hong Kong, Macau and Taiwan rights. The China Phase 2 enrolled 145 participants; omalizumab was an active comparator without planned statistical testing. Korea’s Yuhan also has a CSU Phase 2 registered in Japan.",
  "selection_inputs": [
    "R01",
    "R04",
    "R05"
  ],
  "assets": [
    {
      "section": "approved",
      "trials": [],
      "date": "2026-11-12",
      "sources": [
        "https://www.novartis.com/news/media-releases/new-long-term-rhapsido-remibrutinib-phase-iii-data-show-sustained-efficacy-through-week-52-chronic-inducible-urticaria-cindu"
      ],
      "source_ids": [
        "urt-nov"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Rhapsido／remibrutinib",
      "asset_en": "Rhapsido / remibrutinib",
      "company": "諾華",
      "company_en": "Novartis",
      "country": "瑞士",
      "country_en": "Switzerland",
      "mechanism": "BTK 抑制劑",
      "mechanism_en": "BTK inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准：CSU／症狀性皮膚劃紋症",
      "stage_en": "US approved: CSU / symptomatic dermographism",
      "indication": "CSU；CIndU 依分型",
      "indication_en": "CSU; subtype-specific CIndU",
      "latest": "RemIND：25 mg 每日兩次；SD 第 1 週反應 41.8% 對 19.2%，原始用藥組第 52 週為 46.8%",
      "latest_en": "RemIND: 25 mg twice daily; SD Week 1 response 41.8% vs 19.2%; original-treatment Week 52 response 46.8%"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "2026-04",
      "sources": [
        "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780&type=display"
      ],
      "source_ids": [
        "urt-sanofi-label"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Dupixent／dupilumab",
      "asset_en": "Dupixent / dupilumab",
      "company": "賽諾菲／再生元",
      "company_en": "Sanofi / Regeneron",
      "country": "法國／美國",
      "country_en": "France / US",
      "mechanism": "IL-4Rα 抗體",
      "mechanism_en": "IL-4Rα antibody",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "2 歲以上、H1 抗組織胺仍有症狀的 CSU",
      "indication_en": "CSU, age 2+, symptomatic despite H1 antihistamines",
      "latest": "標籤已擴及 2 歲以上；不將舊的 12 歲門檻沿用",
      "latest_en": "Label includes age 2+; prior age-12 threshold is superseded"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://www.gene.com/download/pdf/xolair_prescribing.pdf"
      ],
      "source_ids": [
        "urt-xolair"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Xolair／omalizumab",
      "asset_en": "Xolair / omalizumab",
      "company": "羅氏／Genentech／諾華",
      "company_en": "Roche / Genentech / Novartis",
      "country": "瑞士／美國",
      "country_en": "Switzerland / US",
      "mechanism": "抗 IgE 抗體",
      "mechanism_en": "Anti-IgE antibody",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "CSU",
      "indication_en": "CSU",
      "latest": "已核准的抗 IgE 比較基準",
      "latest_en": "Approved anti-IgE comparator"
    },
    {
      "section": "clinical",
      "trials": [],
      "date": "2026-11-05",
      "sources": [
        "https://ir.celldex.com/node/16806"
      ],
      "source_ids": [
        "urt-celldex"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "barzolvolimab",
      "asset_en": "barzolvolimab",
      "company": "Celldex",
      "company_en": "Celldex",
      "country": "美國",
      "country_en": "US",
      "mechanism": "抗 KIT 抗體",
      "mechanism_en": "Anti-KIT antibody",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "三期結果已公布；擬送件",
      "stage_en": "Phase 3 results reported; filing planned",
      "indication": "CSU；ColdU／皮膚劃紋症",
      "indication_en": "CSU; ColdU / dermographism",
      "latest": "CSU 三期達終點；計畫 2027 年送件",
      "latest_en": "CSU Phase 3 endpoints met; 2027 filing planned"
    },
    {
      "section": "clinical",
      "trials": [],
      "date": "2026-09-20",
      "sources": [
        "https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-announces-positive-topline-results-cue-221-phase-2"
      ],
      "source_ids": [
        "urt-cue"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "CUE-221／UB-221",
      "asset_en": "CUE-221 / UB-221",
      "company": "Cue／Ascendant／Genesis；起源聯生藥",
      "company_en": "Cue / Ascendant / Genesis; originated at United BioPharma",
      "country": "台灣起源／中國試驗／美國授權",
      "country_en": "Taiwan origin / China trial / US licensee",
      "mechanism": "抗 IgE 抗體",
      "mechanism_en": "Anti-IgE antibody",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "二期結果；擬二 b／三期",
      "stage_en": "Phase 2 results; Phase 2b/3 planned",
      "indication": "CSU",
      "indication_en": "CSU",
      "latest": "中國二期 145 人；未預設與 Xolair 的統計比較",
      "latest_en": "145 in China Phase 2; no planned statistical comparison with Xolair"
    },
    {
      "section": "clinical",
      "trials": [
        "jRCT2031260326"
      ],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://jrct.mhlw.go.jp/latest-detail/jRCT2031260326"
      ],
      "source_ids": [
        "urt-yuhan"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "lesigercept／YH35324",
      "asset_en": "lesigercept / YH35324",
      "company": "有韓洋行（Yuhan）",
      "company_en": "Yuhan",
      "country": "韓國",
      "country_en": "South Korea",
      "mechanism": "IgE 捕捉融合蛋白",
      "mechanism_en": "IgE-trap fusion protein",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "二期",
      "stage_en": "Phase 2",
      "indication": "CSU",
      "indication_en": "CSU",
      "latest": "日本 jRCT 登錄二期；不是上市許可",
      "latest_en": "Phase 2 registered in Japan; registration is not marketing approval"
    }
  ],
  "number_checks": [
    [
      "U1",
      "第 52 週原始 Rhapsido 組 SD 完全或部分反應率",
      "46.8%",
      "urt-nov",
      "46.8%"
    ],
    [
      "U2",
      "同分型第 1 週完全或部分反應率",
      "41.8%",
      "urt-nov",
      "41.8%"
    ],
    [
      "U3",
      "該第 1 週安慰劑反應率",
      "19.2%",
      "urt-nov",
      "19.2%"
    ],
    [
      "U4",
      "RemIND 劑量",
      "25 mg，每日兩次",
      "urt-nov",
      "25 mg twice daily"
    ],
    [
      "U5",
      "CUE-221 中國二期收案",
      "145 人",
      "urt-cue",
      "145"
    ]
  ],
  "not_listed_unconfirmed": [],
  "not_listed_note": "",
  "not_listed_note_en": "",
  "summary_expected": {
    "total": 6,
    "approved": 3,
    "clinical": 3,
    "phase2_3": 0,
    "discontinued": 0,
    "asia": 2,
    "taiwan": 1
  }
}
